| Sep'19 | Sep'18 | Sep'17 | Sep'16 | Sep'15 | Sep'14 | Sep'13 | Sep'12 | Sep'11 | Sep'10 |
|---|---|---|---|---|---|---|---|---|---|
Operating activities: | |||||||||
Net loss | |||||||||
-790 | -194 | 884 | -3,230 | 1,099 | -1,070 | 773 | -6,317 | 2,302 | -2,691 |
Adjustments to reconcile net loss to net cash provided by operating activities, net of acquisition: | |||||||||
Depreciation and amortization | |||||||||
2,717 | 1,875 | 1,680 | 1,556 | 1,437 | 1,597 | 1,723 | 2,278 | 2,134 | 2,323 |
Employee stock compensation expense | |||||||||
278 | 134 | 19 | 45 | 79 | 84 | 225 | 83 | 153 | 226 |
Decrease in fair value of warrant liability | |||||||||
- | - | - | -189 | -487 | 918 | -601 | -73 | -1,759 | - |
Provision for doubtful accounts, net | |||||||||
- | - | - | - | - | -33 | - | - | - | - |
Liability incurred on settlement of lease | |||||||||
- | - | - | - | - | - | - | - | - | 216 |
Gain on interest rate swaps | |||||||||
- | - | - | - | - | - | - | - | 31 | 72 |
Gain on disposal of property and equipment | |||||||||
-1 | 0 | 5 | -14 | 7 | 21 | 13 | -451 | 9 | 1 |
Unrealized foreign currency gains | |||||||||
159 | 0 | - | - | - | - | - | - | - | - |
Provision for doubtful accounts | |||||||||
-178 | -4 | 0 | 84 | 505 | - | - | - | 16 | 61 |
Impairment of goodwill | |||||||||
- | - | - | 971 | 0 | 374 | - | - | - | - |
Deferred income taxes | |||||||||
- | - | - | - | - | - | - | - | -14 | 12 |
Changes in operating assets and liabilities: | |||||||||
Accounts receivable | |||||||||
3,087 | 589 | 941 | -1,639 | 1,084 | -910 | 25 | -902 | 236 | -650 |
Inventories | |||||||||
-87 | 269 | -540 | -13 | -98 | 185 | -277 | 20 | -37 | -174 |
Income tax accruals | |||||||||
-3 | -82 | 7 | -17 | 10 | -10 | 13 | -39 | - | - |
Income taxes | |||||||||
- | - | - | - | - | - | - | - | -56 | -529 |
Prepaid expenses and other assets | |||||||||
113 | 77 | 14 | 27 | 97 | 345 | 9 | -414 | -17 | -90 |
Accounts payable | |||||||||
1,019 | 980 | -913 | 1,122 | 259 | -863 | -269 | 2,375 | -482 | -86 |
Accrued expenses | |||||||||
849 | 103 | 113 | -621 | -132 | 153 | -378 | 305 | -86 | -709 |
Customer advances | |||||||||
1,156 | 1,610 | - | - | - | - | - | - | - | - |
Customer advances | |||||||||
- | - | -134 | -300 | 424 | 175 | -197 | -559 | -1,010 | 1,719 |
Net cash provided by operating activities | |||||||||
- | - | - | - | 2,104 | 1,684 | - | - | - | - |
Net cash provided by operating activities | |||||||||
1,777 | 3,487 | 1,236 | 1,060 | - | - | 1,519 | -200 | 1,088 | 2,441 |
Investing activities: | |||||||||
Capital expenditures | |||||||||
6,878 | 1,317 | 347 | 1,256 | 1,467 | 490 | 8 | 1,090 | 1,174 | 450 |
Cash paid in acquisition | |||||||||
1,271 | 6,759 | 0 | - | - | - | - | - | - | - |
Proceeds from sale of equipment | |||||||||
0 | 2 | - | - | - | - | - | - | - | - |
Proceeds from sale of equipment | |||||||||
- | - | 8 | 0 | 33 | 0 | 20 | 230 | - | - |
Net cash used by investing activities | |||||||||
- | - | - | - | -1,434 | -490 | - | - | - | - |
Net cash used in investing activities | |||||||||
-8,149 | -8,074 | -339 | -1,256 | - | - | 12 | -860 | -1,174 | -450 |
Financing activities: | |||||||||
Borrowings on capex line of credit | |||||||||
655 | 0 | - | - | - | - | - | - | - | - |
Payments on finance lease liability | |||||||||
88 | 131 | - | - | - | - | - | - | - | - |
Direct common shares purchased by CEO and Board of Directors | |||||||||
- | - | - | - | - | - | 0 | 128 | - | - |
Net proceeds from registered direct offering | |||||||||
- | - | - | - | - | - | - | - | 4,606 | - |
Direct common shares purchased by interim CEO and Board of Directors | |||||||||
- | - | - | - | - | - | - | - | 0 | - |
Payments of long-term debt | |||||||||
909 | 331 | 3,721 | 786 | 786 | 5,516 | 588 | 735 | 1,756 | 599 |
New borrowings on long-term debt | |||||||||
1,271 | 5,500 | 4,500 | 0 | - | 5,500 | - | - | - | - |
Payments of debt issuance costs | |||||||||
94 | 113 | 214 | 68 | 0 | 194 | - | - | - | - |
Proceeds from Class A warrant exercises | |||||||||
- | - | - | - | - | 183 | - | - | - | - |
Payments on revolving line of credit | |||||||||
28,662 | 7,545 | 11,516 | 11,304 | 7,740 | 10,542 | 21,814 | 27,695 | 30,917 | 28,948 |
Borrowings on revolving line of credit | |||||||||
29,725 | 7,545 | 10,158 | 12,576 | 7,624 | 9,329 | 21,785 | 27,793 | 31,068 | 28,384 |
Borrowings on construction loan | |||||||||
4,301 | 0 | - | - | - | - | - | - | - | - |
Proceeds from sale and leaseback | |||||||||
- | - | - | - | - | - | - | - | - | 431 |
Payments of capital lease obligations | |||||||||
- | - | 127 | 277 | 279 | 276 | 330 | 655 | 1,341 | 726 |
Proceeds from exercise of stock options | |||||||||
6 | 1 | 71 | 3 | 0 | 3 | - | - | - | - |
Payment of withholding taxes from net settlement of stock based awards | |||||||||
- | - | - | - | 32 | 0 | - | - | - | - |
Net cash (used) provided by financing activities | |||||||||
- | - | - | - | -1,213 | -1,513 | - | - | - | - |
Net cash provided by financing activities | |||||||||
6,205 | 4,926 | -849 | 144 | - | - | -947 | -1,164 | 1,660 | -1,458 |
Net decrease in cash and cash equivalents | |||||||||
-167 | 339 | - | - | - | - | - | - | - | - |
Effect of exchange rate changes | |||||||||
- | - | - | - | - | -4 | -1 | -18 | -33 | 19 |
Net increase (decrease) in cash and cash equivalents | |||||||||
- | - | 48 | -52 | -543 | -323 | 583 | -2,242 | 1,541 | 552 |
Supplemental disclosure of cash flow information: | |||||||||
Cash paid for interest | |||||||||
566 | 233 | 230 | 312 | 264 | 389 | 649 | 715 | - | - |
Cash paid for income taxes | |||||||||
- | - | - | - | 4 | 17 | 3 | 12 | - | - |
Conversion of preferred shares to common shares | |||||||||
0 | 1,000 | 150 | - | - | 150 | - | - | - | - |
Preclinical Research Services acquisition: | |||||||||
Assets acquired | |||||||||
- | - | 0 | - | - | - | - | - | - | - |
Liabilities assumed | |||||||||
- | - | 0 | - | - | - | - | - | - | - |
Preferreed stock dividends accrued, but not paid | |||||||||
- | - | - | - | - | - | - | - | 991 | - |
Common shares issued | |||||||||
- | - | 0 | - | - | 48 | 81 | 106 | -657 | - |
Equipment financed under capital leases | |||||||||
- | - | - | 303 | 0 | 114 | 0 | 356 | 1,888 | - |
Fair value of Class A Warrants exercised | |||||||||
- | - | - | - | - | 854 | - | - | - | - |
Termination of capital lease obligation | |||||||||
- | - | - | - | - | - | 0 | 322 | 0 | - |
Smithers Avanza Toxicology Services LLC acquisition | |||||||||
Net loss | |||||||||
0 | - | - | - | - | - | - | - | - | - |
Assets acquired | |||||||||
3,384 | 0 | - | - | - | - | - | - | - | - |
Liabilities assumed | |||||||||
1,719 | 0 | - | - | - | - | - | - | - | - |
Common shares issued | |||||||||
394 | 0 | - | - | - | - | - | - | - | - |
Cash paid | |||||||||
1,271 | 0 | - | - | - | - | - | - | - | - |
Seventh Wave Laboratories LLC acquisition | |||||||||
Assets acquired | |||||||||
0 | 10,052 | - | - | - | - | - | - | - | - |
Liabilities assumed | |||||||||
0 | 818 | - | - | - | - | - | - | - | - |
Common shares issued | |||||||||
0 | 2,475 | - | - | - | - | - | - | - | - |
Cash paid | |||||||||
0 | 6,759 | - | - | - | - | - | - | - | - |